Magnetic Resonance - Technology Information Portal Welcome to MRI Technology••
Info
  Sheets


Out-
      side
 



 
 'Gadobenate Dimeglumine' 
SEARCH FOR    
 
  2 3 5 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Result : Searchterm 'Gadobenate Dimeglumine' found in 1 term [] and 4 definitions []
1 - 5 (of 5)     
Result Pages : [1]
MRI Resources 
Directories - Service and Support - Liver Imaging - Colonography - Cardiovascular Imaging - Breast Implant
 
Gadobenate DimeglumineInfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.
 
Short name: Gd-BOPTA, generic name: Gadobenate dimeglumine
A paramagnetic MRI contrast agent (small molecular weight Gd-chelate) with 0.5 and 0.25 molar concentration.
The albumin-mediated relaxation enhancement may result in advantages for Gd-BOPTA over Gd-DTPA and other gadolinium agents in poorly vascularized, small, or lesions with low enhancement and in tumors with high concentrations of albumin. The substance is excreted partly by the kidneys (75-90%), partly by the biliary system (10-25%). The uptake in the liver is about 5% in humans. It is bolus injectable.
See Contrast Agents and MultiHance®.

spacer
 
• Share the entry 'Gadobenate Dimeglumine':  Facebook  Twitter  LinkedIn  

• View the NEWS results for 'Gadobenate Dimeglumine' (1).Open this link in a new window.
 
Further Reading:
  Basics:
MultiHance Package Insert(.pdf)
   by www.fda.gov    
  News & More:
PRAC concludes assessment of gadolinium agents used in body scans and recommends regulatory actions, including suspension for some marketing authorisations
Friday, 10 March 2017   by www.satprnews.com    
MRI Resources 
Quality Advice - Case Studies - Software - MRA - Absorption and Emission - Journals
 
MultiHance®InfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.MRI Resource Directory:
 - Contrast Agents -
 
MultiHance® is a paramagnetic contrast agent for use in diagnostic magnetic resonance imaging (MRI) of the liver and central nervous system. MultiHance® is a small molecular weight chelate, which tightly binds the Gd atom. The substance is excreted partly by the kidneys, partly by the biliary system, which is especially unique.
MultiHance® is indicated, for the detection of focal liver lesions in patients with known or suspected primary liver cancer (e.g. hepatocellular carcinoma) or metastatic disease.
MultiHance® is also indicated in brain MRI and spine MRI where it improves the detection of lesions and provides diagnostic information additional to that obtained with unenhanced MRI.
Gd-BOPTA-enhanced MRA can provide superior vascular signal intensity and SNR, as compared with Gd-DTPA, due to its higher relaxivity, even at lower doses.
1 ml of solution MultiHance® contains: (0.5M) gadobenate dimeglumine 529 mg = gadobenic acid 334 mg + meglumine 195 mg. Viscosity at 37°C: 5.3 mPa
WARNING: NEPHROGENIC SYSTEMIC FIBROSIS Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with acute or chronic severe renal insufficiency (glomerular filtration rate less than 30 mL/min/1.73m2), or acute renal insufficiency of any severity due to the hepato-renal syndrome or in the perioperative liver transplantation period.


Drug Information and Specification
NAME OF COMPOUND Gadobenate dimeglumine, Gd-BOPTA, E7155
DEVELOPER Bracco
CENTRAL MOIETY Gd2+
CONTRAST EFFECT T1, predominantly positive enhancement
RELAXIVITY r1=9.7, r2=12.5, B0=0.5 T
PHARMACOKINETIC Extracellular, hepatobiliary
OSMOLALITY 1970 mosm/kg
CONCENTRATION 334 mg/ml
DOSAGE 0.05 mmol/kg for Liver MRI
0.1 mmol/kg for CNS MRI
PREPARATION Solution for injection
INDICATION CNS, Liver MRI
DEVELOPMENT STAGE For sale
DISTRIBUTOR See below
PRESENTATION Vials of 5, 10, 15 and 20 mL, 50 and 100 mL Multipacks (Pharmacy Bulk Package)
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT

Distribution Information
TERRITORY TRADE NAME DEVELOPMENT
STAGE
DISTRIBUTOR
EU MultiHance® for sale Bracco Diagnostics
USA MultiHance® for sale Bracco Diagnostics
Australia MultiHance® for sale Bracco Pty Ltd
Japan E7155 Bracco-Eisai Co., Ltd.

spacer

• View the DATABASE results for 'MultiHance®' (9).Open this link in a new window


• View the NEWS results for 'MultiHance®' (1).Open this link in a new window.
 
Further Reading:
  Basics:
Important Drug Warning for Gadolinium-Based Contrast Agents
Wednesday, 12 September 2007   by www.ismrm.org    
MultiHance Package Insert(.pdf)
   by www.fda.gov    
  News & More:
FDA Expands Pediatric Age Range for MultiHance Contrast Agent
Tuesday, 30 January 2018   by www.empr.com    
MAGNETIC RESONANCE IMAGING OF FOCAL LIVER LESIONS(.pdf)
2002
BRACCO DIAGNOSTICS' MULTIHANCE EARNS FDA APPROVAL
Wednesday, 24 November 2004   by salesandmarketingnetwork.com    
MRI Resources 
Spectroscopy pool - IR - Claustrophobia - Most Wanted - MR Guided Interventions - Patient Information
 
Hepatobiliary ChelatesInfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.
 
Hepatobiliary chelates used in MRI are paramagnetic contrast agents consisting of a metal ion bound to an organic ligand. Paramagnetic metal ions such as gadolinium improve the MRI signal, but the toxicity of these uncomplexed metal ions makes the use of a chelate to bind the metal ion essential. Due to the hepatocyte uptake of this chelate complex, the different contrast between normal parenchyma and liver lesions improves the detection and characterization of specific diseases. In addition, the hepatobiliary excretion allows the assessment of the hepatobiliary system.
Chelates for hepatobiliary imaging: MultiHance® (Gadobenate Dimeglumine), Teslascan® (Mangafodipir Trisodium), Gd-HIDA, Cr-HIDA, and Fe-EHPG IronIII or other derivatives. See also Hepatobiliary Contrast Agents, Liver Imaging.
spacer

• View the DATABASE results for 'Hepatobiliary Chelates' (6).Open this link in a new window

 
Further Reading:
  Basics:
MR contrast agents: Applications in hepatobiliary imaging
Thursday, 11 November 2010   by www.appliedradiology.com    
MRI Resources 
Coils - Stimulator pool - Raman Spectroscopy - Distributors - Brain MRI - Pathology
 
Intracellular Contrast AgentsInfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.MRI Resource Directory:
 - Contrast Agents -
 
Contrast agent with a preferential intracellular distribution.
Intracellular agents (such as manganese derivatives and ultrasmall superparamagnetic iron oxide), exhibit a flow- and metabolism-dependent uptake. These properties may allow delayed imaging, similar to isotopic methods.
Phospholipid liposomes are rapidly sequestered by the cells in the reticuloendothelial system (RES), primarily in the liver. For imaging of the liver, liposomes may be labeled with MR contrast medium, both positive (T1-shortening) paramagnetic media, and negative (T2-shortening) superparamagnetic media.
Several other nonliposome MR contrast media are also taken up by the RES, e.g.:
superparamagnetic iron oxide (SPIO)
ultrasmall superparamagnetic iron oxide (USPIO)
monocrystalline iron oxide nanoparticle (MION)

Other MR contrast agents accumulate selectively in the hepatocytes, e.g.:
gadoxetic acid (Gd-EOB-DTPA)
gadobenate dimeglumine (Gd-BOPTA)
mangafodipir trisodium (Mn-DPDP)
spacer

• View the DATABASE results for 'Intracellular Contrast Agents' (3).Open this link in a new window

MRI Resources 
Implant and Prosthesis pool - Journals - Mass Spectrometry - Pacemaker - Pediatric and Fetal MRI - Coils
 
Reticuloendothelial Contrast AgentsInfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.MRI Resource Directory:
 - Contrast Agents -
 
Liver imaging with gadolinium contrast enhanced MRI is sometimes not sufficient for a reliable diagnosis of liver lesions. For this reasons, special liver Contrast agents that are targeted to the reticuloendothelial system (RES), have been developed to improve both detection and characterization of liver and spleen lesions. Reticuloendothelial Contrast Agents, as e.g. superparamagnetic iron oxides (SPIO), are taken up by healthy liver tissue but not tumors.
These RES targeted contrast agents provide a prolonged imaging window and enough time for high spatial resolution or multiple breath hold images. Reticuloendothelial contrast agents have an increased sensitivity for the detection of small liver lesions (e.g., metastases), compared with gadolinium enhanced MRI and spiral CT. At higher field strengths with an increased signal to noise ratio the susceptibility effect with iron oxide particles may be enhanced.
Other new agents (Gadobenate Dimeglumine, Gadoxetic Acid) have both an initial extracellular circulation and a delayed liver-specific uptake. Since a considerable part of these contrast agents is excreted in the bile, functional biliary imaging can diagnose biliary anomalies, postoperative bile leaks, and anastomotic strictures. Other agents, such as liposomes (with encapsulated Gd-DTPA) or DOTA complexes are in different development stages.
See also Hepatobiliary Contrast Agents, Gadolinium Oxide, Superparamagnetic Iron Oxide and Liposomes.
spacer

• View the DATABASE results for 'Reticuloendothelial Contrast Agents' (3).Open this link in a new window

MRI Resources 
Jobs pool - Societies - Musculoskeletal and Joint MRI - Anatomy - Nerve Stimulator - Spectroscopy pool
 
     1 - 5 (of 5)     
Result Pages : [1]
 Random Page
 
Share This Page
FacebookTwitterLinkedIn

MR-TIP    
Community   
User
Pass
Forgot your UserID/Password ?  



The impact of TTIP/TPP on the MRI scanner market will bring :
more variety 
better scanners 
more risk 
less regulation 
cheaper scanners 
Lost in Translation 
no change at all 

Look
      Ups





MR-TIP.com uses cookies! By browsing MR-TIP.com, you agree to our use of cookies.

Magnetic Resonance - Technology Information Portal
Member of SoftWays' Medical Imaging Group - MR-TIP • Radiology-TIP • US-TIP • 
Copyright © 2003 - 2018 SoftWays. All rights reserved. [ 22 January 2019]
Terms of Use | Privacy Policy | Advertising
 [last update: 2018-03-08 05:11:00]